Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT06667960 is registered in ClinicalTrials.gov with Salubris Biotherapeutics Inc as lead sponsor.

NCT NCT06667960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06667960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Lead sponsor
Salubris Biotherapeutics Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 23, 2024
Completion date
August 1, 2028
Enrollment
255 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor